"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."
Top Sponsors
Top Collaborators
Trials By Phase
Recruitment Status
Top Conditions
Intervention Types
Top Intervention Names
Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
1
NSABP Foundation Inc
1
Clinical Trials at Maryland Oncology - Hematology PA
During the past decade, Maryland Oncology - Hematology PA conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
2018-03-23
2024-04-26
Recruiting
631
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Oncology - Hematology PA"
#1 collaborator was "Genentech, Inc." with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Maryland Oncology - Hematology PA
According to Clinical.Site data, the most researched conditions in "Maryland Oncology - Hematology PA" are
"Triple Negative Breast Cancer" (1 trials) and "Urothelial Cancer" (1 trials). Many other conditions were trialed in "Maryland Oncology - Hematology PA" in a lesser frequency.
Clinical Trials Intervention Types at Maryland Oncology - Hematology PA
Most popular intervention types in "Maryland Oncology - Hematology PA" are "Drug" (2 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (1 trials), "Docetaxel" (1 trials), "Erdafitinib" (1 trials), "Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)" (1 trials) and "Pembrolizumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Maryland Oncology - Hematology PA
The vast majority of trials in "Maryland Oncology - Hematology PA" are
2 trials for "All" genders.
Clinical Trials Status at Maryland Oncology - Hematology PA
Currently, there are NaN active trials in "Maryland Oncology - Hematology PA".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Maryland Oncology - Hematology PA,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Maryland Oncology - Hematology PA, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".